middle.news
Radiopharm Theranostics Advances 177Lu-RAD204 Trial with DSMC Green Light
2:48am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Radiopharm Theranostics Advances 177Lu-RAD204 Trial with DSMC Green Light
2:48am on Monday 2nd of June, 2025 AEST
Key Points
DSMC approves continuation and dose escalation in Phase 1 trial
Second cohort dose increased from 40mCi to 60mCi
Trial expands beyond NSCLC to include five additional tumor types
Enrollment of first two cohorts expected by mid-2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Radiopharm Theranostics (ASX:RAD)
OPEN ARTICLE